East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
Growing International Pharmaceutical Company Awards $1.2 Million in Studies to
eResearchTechnology for Cardiac Safety Monitoring and Information Distribution
Services
Program Award Includes a Series of Studies Across Several Phases for Multiple
Indications in Key Clinical Development Program
PHILADELPHIA, March 23 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has been awarded studies
totaling approximately $1.2 million in cardiac safety monitoring and services
from a growing international pharmaceutical organization for one of its key
drugs in clinical trials.
The award covers a program of Phase I, Phase II, and Phase IV studies that
target several indications and will be conducted at more than 225 research sites
distributed across the U.S. eRT will provide comprehensive support and more
than 225 units of digital 12-lead ECG equipment designed to facilitate
collection of cardiac safety data that is subsequently provided to eRT for
analysis. eRT will perform digital collection, measurement, interpretation,
review, and distribution of cardiac safety data through its EXPeRT workflow
enabled data handlingtechnology, the first solution in production that was
designed explicitly to meet emerging international regulatory guidance and
technical standards.
"eRT is uniquely equipped to collaborate closely with this drug developer in
execution of a complex clinical trial program that includes studies spread
across several phases, with multiple indications and diverse patient
populations," said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT. "Increasingly, pharmaceutical organizations
are concluding that such sophisticated programs benefit from a cardiac safety
partner with the capacity and scientific capability to deliver a consistent
services platform that helps to ensure overall success."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The studies pertaining to these awards may be canceled by the sponsor
at its sole discretion. As a result, actual results may differ materially from
any financial outlooksstated herein. Further information on potential factors
that could affect the company's financial results can be found in the company's
Reports on Forms 10-K and 10-Q filed with the Securities and Exchange
Commission.
DATASOURCE: eResearchTechnology,Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or
Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology
Web site: http://www.ert.com/